124 related articles for article (PubMed ID: 34655194)
21. BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies.
Conant JL; Czuchlewski DR
Int J Lab Hematol; 2019 May; 41 Suppl 1():126-130. PubMed ID: 31069976
[TBL] [Abstract][Full Text] [Related]
22. BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with
Takahashi T; Ichikawa S; Ichinohasama R; Harigae H
Leuk Lymphoma; 2020 May; 61(5):1265-1267. PubMed ID: 31876209
[No Abstract] [Full Text] [Related]
23. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Scheuring UJ; Pfeifer H; Wassmann B; Bruck P; Atta J; Petershofen EK; Gehrke B; Gschaidmeier H; Hoelzer D; Ottmann OG
Blood; 2003 Jan; 101(1):85-90. PubMed ID: 12393581
[TBL] [Abstract][Full Text] [Related]
24. [Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world].
Wan YL; Wang Y; Liu BC; Liu X; Gong XY; Zhao XL; Wang TY; Jiang EL; Feng SZ; Han MZ; Qiu LG; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):886-891. PubMed ID: 27801322
[TBL] [Abstract][Full Text] [Related]
25. Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.
Chiaretti S; Messina M; Grammatico S; Piciocchi A; Fedullo AL; Di Giacomo F; Peragine N; Gianfelici V; Lauretti A; Bareja R; Martelli MP; Vignetti M; Apicella V; Vitale A; Li LS; Salek C; Elemento O; Inghirami G; Weinstock DM; Guarini A; Foà R
Br J Haematol; 2018 Jun; 181(5):642-652. PubMed ID: 29675955
[TBL] [Abstract][Full Text] [Related]
26. Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia.
Rambaldi A; Attuati V; Bassan R; Neonato MG; Viero P; Battista R; Di Bona E; Rossi G; Pogliani E; Ruggeri M; Amaru R; Rivolta A; Giudici G; Biondi A; Barbui T
Leuk Lymphoma; 1996 May; 21(5-6):457-66. PubMed ID: 9172811
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
Sanchez R; Ayala R; Alonso RA; Martínez MP; Ribera J; García O; Sanchez-Pina J; Mercadal S; Montesinos P; Martino R; Barba P; González-Campos J; Barrios M; Lavilla E; Gil C; Bernal T; Escoda L; Abella E; Amigo ML; Moreno MJ; Bravo P; Guàrdia R; Hernández-Rivas JM; García-Guiñón A; Piernas S; Ribera JM; Martínez-López J
Ann Hematol; 2017 Jul; 96(7):1069-1075. PubMed ID: 28451802
[TBL] [Abstract][Full Text] [Related]
28. p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia.
Lemes A; Gómez Casares MT; de la Iglesia S; Matutes E; Molero MT
Cancer Genet Cytogenet; 1999 Aug; 113(1):100-2. PubMed ID: 10459357
[TBL] [Abstract][Full Text] [Related]
29. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
[TBL] [Abstract][Full Text] [Related]
30. Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.
Chiaretti S; Tavolaro S; Ghia EM; Ariola C; Matteucci C; Elia L; Maggio R; Messina M; Ricciardi MR; Vitale A; Ritz J; Mecucci C; Guarini A; Foà R
Haematologica; 2007 May; 92(5):619-26. PubMed ID: 17488685
[TBL] [Abstract][Full Text] [Related]
31. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group.
Beyermann B; Agthe AG; Adams HP; Seeger K; Linderkamp C; Goetze G; Ludwig WD; Henze G
Blood; 1996 Feb; 87(4):1532-8. PubMed ID: 8608244
[TBL] [Abstract][Full Text] [Related]
32. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia.
Thakral B; Jain N; Tang G; Konoplev S; Vega F; Medeiros LJ; Wang SA
Ann Diagn Pathol; 2021 Aug; 53():151767. PubMed ID: 34118580
[TBL] [Abstract][Full Text] [Related]
33. Expression of Th17 and CD4
Xiang M; Guo L; Ma Y; Li Y
Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2405-2410. PubMed ID: 28167485
[TBL] [Abstract][Full Text] [Related]
34. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
36. Immune regulation of hydrogen sulfide in children with acute lymphoblastic leukemia.
Du S; Jia Y; Tang H; Sun Y; Wu W; Sun L; Du J; Geng B; Tang C; Jin H
Chin Med J (Engl); 2014; 127(21):3695-9. PubMed ID: 25382321
[TBL] [Abstract][Full Text] [Related]
37. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
38.
Jain S; Abraham A
Arch Pathol Lab Med; 2020 Feb; 144(2):150-155. PubMed ID: 31644323
[TBL] [Abstract][Full Text] [Related]
39. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.
Iacobucci I; Lonetti A; Venturi C; Ferrari A; Papayannidis C; Ottaviani E; Abbenante MC; Paolini S; Bresciani P; Potenza L; Parisi S; Cattina F; Soverini S; Russo D; Luppi M; Martinelli G
Leuk Res; 2014 May; 38(5):581-5. PubMed ID: 24630366
[TBL] [Abstract][Full Text] [Related]
40. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
